RGEN · Healthcare
REPLIGEN CORP
Smart-money confidence
· 1 of 3 sources firing
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
32
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
◆ Next steps
Interested in REPLIGEN CORP? Here's what to do with it.
◇
Compare with other stocks
Sort 7,111 stocks by confidence, holders, or Congress signal
◈
Backtest the strategy
See how the model has done historically before you commit real money
✉
Get the weekly digest
One email on Sunday · what changed in the model this week
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$7.4B
Industry
Medical Instruments & Supplies
Sector
Healthcare
Exchange
NasdaqGS
About REPLIGEN CORP
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It…
Who's behind the signal
Every informed buyer we can see on RGEN, across all three feeds.
Hedge funds · 6
Gotham Asset Mgmt (Greenblatt)
Increased +17%
Point72 (Steve Cohen)
Decreased −30%
Citadel Advisors
Decreased −17%
Millennium Management (Englander)
Decreased −20%
Bridgewater Associates (Dalio)
Decreased −77%
AQR Capital Management
Decreased −6%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trade history · 1
Every disclosed buy & sell on record — STOCK Act filings
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2022-05-05 | Josh Gottheimer · D-NJ | House | BOUGHT | $1,001 - $15,000 |
Not a model pick — but on our radar.
REPLIGEN CORP isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
1
Increasing
5
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+17%
0.0% of Gotham Asset Mgmt's portfolio
Trust weight: 1.1×
% of portfolio
0.3%
Position change
−30%
0.3% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.2%
Position change
−17%
0.2% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−20%
0.1% of Millennium Management's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
−77%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−6%
0.0% of AQR Capital Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to REPLIGEN CORP
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell REPLIGEN CORP or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime